Yale's Autism Biomarkers Consortium for Clinical Trials (ABC-CT) is a major research effort exploring how biomarkers (like EEG patterns) could make autism diagnosis more objective and accessible. This could help families by reducing wait times and costs for evaluations. The SPARK study at Yale is also collecting genetic data to uncover autism-linked biomarkers—families can participate by providing saliva samples.

For young kids (ages 3–6), Yale’s ABC-CT preschool study is actively recruiting to improve early detection tools. Biomarkers might one day complement behavioral assessments, offering clearer insights for personalized therapies.

Sources:
[Yale ABC-CT](https://medicine.yale.edu/lab/mcpartland/abc-ct/)
[SPARK Study](https://www.yalemedicine.org/c....linical-trials/spark